Agios Pharmaceuticals, Inc.
Clinical trials sponsored by Agios Pharmaceuticals, Inc., explained in plain language.
-
Promising new drug shows hope for rare anemia patients
Disease control CompletedThis study tested a drug called mitapivat (AG-348) in 52 adults with pyruvate kinase deficiency, a rare genetic condition that causes red blood cells to break down too quickly, leading to anemia. The goal was to see if different doses of the drug are safe and help control the dis…
Phase: PHASE2 • Sponsor: Agios Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New hope for rare blood disorder: Long-Term drug study shows promise
Disease control CompletedThis study looked at the long-term safety and effectiveness of the drug mitapivat in 90 adults with pyruvate kinase deficiency, a rare genetic blood disorder that causes red blood cells to break down too quickly. Participants had already completed earlier studies of mitapivat and…
Phase: PHASE3 • Sponsor: Agios Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New drug AG-181 tested in healthy people for first time
Knowledge-focused CompletedThis early-stage trial tested the safety and tolerability of a new drug called AG-181 in 88 healthy volunteers. Researchers gave single or multiple doses to see how the body processes the drug and whether it causes any side effects. The study also looked at how food affects drug …
Phase: PHASE1 • Sponsor: Agios Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC